Back to Results
First PageMeta Content
Ivacaftor / Phenols / Quinolones / Cystic fibrosis transmembrane conductance regulator / Cystic fibrosis / Vertex Pharmaceuticals / Ion channel / CFTR / Cystic Fibrosis Foundation / Biology / Health / Anilides


Session 1: Generating and Interpreting Data in Ultra-rare Patient Subsets in Non-oncologic Diseases
Add to Reading List

Open Document

File Size: 3,34 MB

Share Result on Facebook

City

Bethesda / Boston / /

Company

Vertex Pharmaceuticals / Development Vertex Pharmaceuticals Incorporated / /

Country

United States / /

Event

Product Issues / /

Facility

Duke University / Robert Temple / /

MedicalCondition

Genetic Disease / Disease / CF Disease / *cystic fibrosis / Acceptable benefit/risk profile Cystic Fibrosis / /

NaturalFeature

Defect Low Chloride Flow CFTR channel / /

Organization

Duke University / FDA / /

Person

Van Goor / Janet Woodcock / Andrew Mulberg / David Goldstein / Anthony Durmowicz / Jeffrey Chodakewitz / Marshall Summar / Mike Pacanowski / Ivacaftor Jeffrey Chodakewitz / Jeffrey A Chodakewitz / /

Position

Head / /

Product

CFTR* channel function / processing / /

ProvinceOrState

Maryland / /

RadioStation

CFTR / /

Technology

drug development / /

SocialTag